Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Goserelin acetate, Goserelin (Zoladex), Goserelin acetate (Zoladex), Zoladex, Zoladex® LA, LHRH agonist, Triptorelin, Leuprolide
Goserelin · 5 trials · 4 indications
The number of participants for whom neither objective disease progression or death (due to any cause) has been observed at Week 24 over the number of randomised participants x 100.
| Arm | Type | Description |
|---|---|---|
| 2 (CMF scheme) | EXPERIMENTAL | 6 cycles CMF scheme (cyclophosphamide, methotrexate, fluorouracil) |
| 1 (Nol + Zol) | EXPERIMENTAL | Zoladex (3 years) combined with Nolvadex (5 years) |
| Immediate ADT | OTHER | - |
| Deferred ADT | OTHER | - |
| I | ACTIVE_COMPARATOR | Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer |
| II | EXPERIMENTAL | Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer |
| ZOLADEX 10.8 mg | EXPERIMENTAL | ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks |
| ZOLADEX 3.6 mg | EXPERIMENTAL | ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks |
| 1 | EXPERIMENTAL | Zoladex 3-month depot |
| 2 | EXPERIMENTAL | Zoladex 1-month depot |
| Name | Type | Description |
|---|---|---|
| Cyclophosphamide | DRUG | Cyclophosphamide 600mg/m2 |
| Methotrexate | DRUG | Methotrexate 40mg/m2 |
| Fluorouracil implant | DRUG | Fluorouracil 600mg/m2 |
| Goserelin | DRUG | Zoladex 3.6mg/28 days for 3 years |
| Tamoxifen | DRUG | Nolvadex 20mg/day for 5 years |
| Goserelin Acetate | DRUG | Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use. |
| adjuvant therapy | PROCEDURE | - |
| radiation therapy | RADIATION | - |
Inclusion Criteria: * Premenopausal patients with histologically verified, lymph node-negative (pT1c-pT3) or lymph node-positive (pT1a-pT3) breast cancer * Hormone receptor-positive status * More than 6 histologically examined lymph nodes * Laboratory parameters 1. hematopoiesis: \> 3500/µl leuk...
Goserelin is used in oncology for prostate cancer and breast cancer, including advanced breast cancer, early-stage breast cancer, and recurrent prostate cancer. It is a small molecule developed by AstraZeneca PLC under the ticker AZN. The clinical program covers hormone-sensitive disease settings in both men and premenopausal women.
Goserelin targets GNRHR, the gonadotropin-releasing hormone receptor, and acts as an agonist at that receptor. By binding GNRHR as an agonist, goserelin suppresses the hormonal signaling that drives growth of hormone-sensitive prostate and breast tumors. This mechanism underlies its use as an androgen deprivation and hormonal therapy approach.
Goserelin is developed and marketed by AstraZeneca PLC, which trades under the ticker AZN. The company is the sponsor behind the goserelin clinical program in prostate cancer and breast cancer, including the Zoladex branded formulation studied in advanced breast cancer.
Goserelin has been studied across Phase 2 and Phase 3 clinical development in prostate cancer and breast cancer. The program includes completed Phase 3 trials in prostate cancer and early-stage breast cancer, plus a completed Phase 2 trial in advanced breast cancer. No active trials are currently listed for this asset.
Goserelin has been evaluated in completed trials including NCT00439751, which compared immediate versus deferred androgen deprivation with goserelin in recurrent prostate cancer after radical radiotherapy, and NCT00423475, which tested radiation therapy with or without goserelin after surgery for recurrent or refractory prostate cancer. Breast cancer studies include NCT00322348 and NCT00309478.
Yes, Zoladex is a brand name for goserelin, and the active form is goserelin acetate. Other names used for the same agent include goserelin acetate and Goserelin Acetate. Searches for Zoladex, goserelin, or goserelin acetate all refer to the same AstraZeneca product.